title: Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
abstract: Changes in gastric pH can impact the dissolution and absorption of compounds presenting pH-dependent solubility. We assessed, in dogs, the effects of gastric pH-modifying agents on the oral absorption of two weakly basic anticancer drugs, dasatinib and GDC-0941. We also tested whether drug-induced hypochlorhydria could be temporarily mitigated using betaine HCl. Pretreatments with pentagastrin, famotidine, betaine HCl, or combinations of famotidine and betaine HCl were administered orally to dogs prior to drug dosing. The gastric pH was measured under each condition for up to 7 h, and the exposure of the compounds tested was calculated. The average gastric pH in fasted dogs ranged from 1.45 to 3.03. Pentagastrin or betaine HCl treatments lowered the pH and reduced its variability between dogs compared to control animals. In contrast, famotidine treatment maintained gastric pH at values close to 7 for up to 5 h, while betaine HCl transiently reduced the pH to approximately 2 in the famotidine-treated dogs. Famotidine pretreatment lowered GDC-0941 exposure by 5-fold, and decreased dasatinib measurable concentrations 30-fold, compared to the pentagastrin-treated dogs. Betaine HCl restored GDC-0941 AUC in famotidine-treated dogs to levels achieved in control animals, and increased dasatinib AUC to 1.5-fold that measured in control dogs. The results confirmed the negative impact of acid-reducing agents on the absorption of weakly basic drugs. They also suggested that betaine HCl coadministration may be a viable strategy in humans treated with acid-reducing agents in order to temporarily reduce gastric pH and restore drug exposure.
authors: Department of Drug Metabolism and Pharmacokinetics, ‡Department of Small Molecule Pharmaceutical Sciences, and §Department of Small Molecule Clinical Pharmacology, Genentech, Inc. , South San Francisco, California 94080, United States.
authors: Jodie
authors: J
authors: Pang
authors: Gena
authors: G
authors: Dalziel
authors: Brian
authors: B
authors: Dean
authors: Joseph A
authors: JA
authors: Ware
authors: Laurent
authors: L
authors: Salphati
mesh_terms: D000042:Absorption / Q000187:drug effects; D000126:Achlorhydria / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001622:Betaine / Q000494:pharmacology; D000069439:Dasatinib; D004285:Dogs; D015738:Famotidine / Q000494:pharmacology; D005753:Gastric Mucosa / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007191:Indazoles / Q000493:pharmacokinetics*; D008297:Male; D010418:Pentagastrin / Q000494:pharmacology; D054328:Proton Pump Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000493:pharmacokinetics*; D013270:Stomach / Q000187:drug effects; D013449:Sulfonamides / Q000493:pharmacokinetics*; D013844:Thiazoles / Q000493:pharmacokinetics*
chemical_list: C532162:2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine; D000970:Antineoplastic Agents; D007191:Indazoles; D054328:Proton Pump Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D013844:Thiazoles; D001622:Betaine; D015738:Famotidine; D010418:Pentagastrin; D000069439:Dasatinib